Home
PYC Therapeutics

PYC Therapeutics Market Share Analysis for April 2026

For more information or to learn how you can be involved with PYC, reach out and get in touch with one of our team members.

Industry: N/A

Domainpyctx.com

Year Founded2001

Employees51 - 200

Annual Revenue--

PYC Therapeutics

PYC Therapeutics (including company regionals)

pyctx.com

See more website traffic and engagement information

Total visits to PYC Therapeutics's top domains

Understand PYC Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

pyctx.com7.2K

See more with Sales Intelligence

Avg. visit duration in PYC Therapeutics's top domains

Analyze PYC Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

pyctx.com00:00:41

See more with Sales Intelligence

Avg. pageviews on PYC Therapeutics's top domains

See how PYC Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

pyctx.com1.76

See more with Sales Intelligence

PYC Therapeutics top competitors by domain

Top similar sites in April 2026, ranked by their affinity

tayshagtx.comCompany NameTaysha Gene Therapies, Inc.Employees51 - 200HQUnited States, Texas, DallasAnnual revenue$25M - $50MTotal visits10.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by PYC Therapeutics

These are the website technologies, by industry, used by PYC Therapeutics top domains

Widget (6)

Twemoji

Conversion & Analytics (3)

Google Analytics

Email Services (3)

Microsoft Exchange Online

Advertising (2)

DoubleClick

More Technologies

6

See all

News & Signals from PYC Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPYC Therapeutics Limited is developing drug candidate PYC-001.PYC Therapeutics (ASX:PYC) has announced progress in the clinical development of its investigational drug candidate PYC-001.

NewsPYC Therapeutics Limited is developing PYC-001 on Apr 15th '26.PYC Therapeutics Limited (ASX:PYC) today announced a significant advancement in its clinical development program for PYC-001, an investigational drug candidate targeting Autosomal Dominant Optic Atrophy (ADOA).

NewsPYC Therapeutics Limited hired Peter Coleman as Independent Non-Executive Chair on Nov 18th '25.PYC Therapeutics (ASX:PYC) has announced a significant step in its board renewal process, appointing former Woodside chief executive Peter Coleman as its new Independent Non-Executive Chair, effective immediately after the company's Annual General Meeting on 18 November 2025...